Clinical Trials

8 results for Prostate Cancer


A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

Square Wave Testosterone Therapy in Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer, Castration-Resistant Prostate Cancer
  • Intervention: Drug: Transdermal Testosterone, Drug: Standard of Care, Enzalutamide
  • Study ID: NCT03734653
View Trial

A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (fl)

  • Condition: Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
  • Intervention: Drug: PF-06821497
  • Study ID: NCT03460977
View Trial

Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
  • Intervention: Drug: Lutetium Lu 177-PSMA-617, Biological: Pembrolizumab
  • Study ID: NCT03805594
View Trial

A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: Enzalutamide, Drug: Relacorilant
  • Study ID: NCT03674814
View Trial

A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide

  • Condition: Prostatic Cancer, Castration-Resistant
  • Intervention: Drug: Darolutamide(Nubeqa, BAY1841788), Drug: Enzalutamide
  • Study ID: NCT04157088
View Trial

Metastasis-directed Therapy in Castration-refractory Prostate Cancer MEDCARE : a Non-randomized Phase 2 Trial

  • Condition: Castration-resistant Prostate Cancer
  • Intervention: Other: Radiotherapy (SBRT) and/or surgery (metastasectomy)
  • Study ID: NCT04222634
View Trial

Princess Margaret Cancer Centre 18F-DCFPyL PET Registry

  • Condition: Carcinoma of Prostate
  • Intervention: Diagnostic Test: 18F-DCFPyL
  • Study ID: NCT03535831
View Trial